IXS - Innexus Biotechnology Inc (TSXV) - Page 5

There was no bad news- nothing has changed since the FEB 7 news came out- 52 million shares traded in 3 weeks at an average price of .45 , and now ANON has managed to knock it down nearly .10 in the past week with volume of about a million. PURE shorting and manipulation - i would like to suggest that there arent that many retailers selling at a loss , but i know there are some. I am in for the longhaul , not interested in selling here , just to watch it run away on the next news release - Royalty Pharma will soon be adding another 15 million to the company's coffers.

Well someone wearing the anonymous cloak had a defininte plan in mind of late - to sell steadily and continually drop the share price. Guess it will be a wait now to see when they are done and where the bottom is. Either it is someone with a very large amount of shares or its a shortseller with very deep pockets.
But every dog has its day - this one wil come back hard on the not too distant future.

Good to know whitetail - that you feel the same about this tech as I. Unfortunately , we may have underestimated some of the negativity involved with some former directors etal. I am almost sure that this rift is behind the selloff the past week or so.
But as you say - we are in it for the long term and altho there may be some shortterm pain i believe in the longrun this one will work out.

IXS has made a deal with Royalty Pharma - big private firm that has done many million of $$ worth of royalty deals on biotech drugs.
Here is a quick overview:The origins of Royalty Pharma can be traced to the 1980s when certain members of the Company’s management and Investment Committee pioneered the use of royalty interests to fund the clinical development of some pioneering biotechnology products such as Amgen’s Neupogen. Subsequently, these members formed two ‘proof of principal’ investment vehicles to acquire the royalty interests and hold them as investments.

Since inception in 1996, through predecessor entities Royalty Pharma has purchased royalties in ten leading marketed biopharmaceuticals: Amgen’s Neupogen/Neulasta®, Genentech’s Rituxan®, Celgene’sThalomid®, Lilly’s and Centocor’s ReoPro®, Centocor’s Retavase®, Chiron’s TOBI®, Norvartis’ Simulect®, Roche’s Zenapax®, Ligand’s Targentin capsules and Bristol Myers’ Zerit. These products generated more than $5 billion in worldwide sales in 2004 and as a group continue to grow at a significant pace. In addition, the Company has purchased the royalty rights of four products that are in late-stage clinical trials: Entereg, Lasofoxifene, Bazedoxifene and Variza.
Royalty Pharma has purchased a second royalty interest from InNexus Biotechnology Inc. in an additional product targeting cancer based on InNexus's Dynamic Cross Linking (DXL) antibody enhancement technology.

Under the terms of the agreement, Royalty Pharma exercised its option to purchase a second royalty interest for $2.5-million. Royalty Pharma purchased a first royalty interest from InNexus for $2-million in April, 2007, and made an additional at-market equity investment in InNexus in the amount of $1-million ($1.01 per share). The total purchase price for the two royalty interests may be increased by up to an additional $30-million for the two products if certain conditions are fulfilled.

Pablo Legorreta, chief executive officer of Royalty Pharma, stated: "We are very excited to be working with Mr. Morhet and purchasing our second royalty interest from InNexus. We are pleased that InNexus has launched its first product based on their DXL technology into preclinical development and look forward to their future products, achievements and successes."

yes gotta be getting close to a bottom - we shall see tomorrow if ANON has anything left in their warchest to dump.

Courtesy of waiter-trader:
InNexus's DXL technology is reporting successful tests that demonstrate increased efficacy in FDA approved Mabs. That is believed to translate into greater cancer killing power. Furthermore, independant third party briefs concluded that the modified Mab is "new matter" and does not infringe on existing patents. Below are comments from a Sloan-Kettering study that concerns Herceptin side effects, no ichy rash this rather heart failure/damage. One of the remarkable features of DXL technology is the ability to out-perform the original Mab with a considerably lower dose. Dosing and side-effects rarely are unrelated, here in DXL 625 and DXL 702 (Zeothymab?) the potential exists for more effective drugs, with increased applications, enormous patient populations, with less side effects at lower cost. These will be fast-tracked at every turn

Yes you timed it very well tito - the motivated seller that had dumped over a million shares at market in the past week or so - has left the building OR run out of shares to dump. I pikced away at it here today as well - but will wait a few more days to see if the seller returns. Its amazing to see that the remaining shareholders dont have much interest in selling, as can be witnessed by the rise in SP on low volume.